0.9028

6.23% -0.0602

Cardiff Oncology Inc (CRDF)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split

Cardiff Oncology Inc stock is traded at $0.9028, with a volume of 442.64K. It is down -6.23% in the last 24 hours and up +2.62% over the past month. Cardiff Oncology Inc is a clinical-stage biotechnology company that leverages PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies for various cancers with unmet medical needs. The company focuses on targeting tumor vulnerabilities with treatment combinations of onvansertib, its oral and selective PLK1 inhibitor, and standard-of-care (SoC) therapeutics. The firm's clinical program pipeline focuses on indications such as RAS-mutated metastatic colorectal cancer (mCRC), investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC), metastatic triple negative breast cancer (mTNBC), and Chronic Myelomonocytic Leukemia (CMML). Geographically, it operates only in the United States.

Previous Close:

$0.963

Open:

$0.95

24h Volume:

442.64K

Relative Volume:

0.30

Market Cap:

$70.23M

Revenue:

$525.00K

Net Income/Loss:

$-44.76M

P/E Ratio:

-1.3572

EPS:

-0.6652

Net Cash Flow:

$-37.46M

1W Performance:

-12.33%

1M Performance:

+2.62%

6M Performance:

-42.11%

1Y Performance:

-62.99%

1-Day Range:

$0.90

$0.963

1-Week Range:

$0.90

$1.13

52-Week Range:

$0.7566

$3.31

Cardiff Oncology Inc Stock (CRDF) Company Profile

Name

Cardiff Oncology Inc

Sector

Healthcare (1089)

Industry

Biotechnology (604)

Phone

858-952-7570

Address

11055 FLINTKOTE AVENUE, SAN DIEGO, CA

Employee

Twitter

@cardiffoncology

Next Earnings Date

2026-08-04

Latest SEC Filings

CRDF's Discussions on Twitter

Compare CRDF vs VRTX, REGN, ARGX, RVMD, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
CRDF Cardiff Oncology Inc	0.9028	74.92M	525.00K	-44.76M	-37.46M	-0.6652
VRTX Vertex Pharmaceuticals Inc	516.25	128.19B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	806.82	82.72B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	992.77	53.26B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	215.15	43.66B	742.00K	-1.37B	-1.07B	-7.0731
ONC Beone Medicines Ltd Adr	362.23	39.31B	5.76B	514.49M	1.10B	4.4813

Cardiff Oncology Inc Stock (CRDF) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-05-26	Initiated	Noble Capital Markets	Outperform
Jul-08-25	Initiated	Ladenburg Thalmann	Buy
Jun-24-25	Initiated	Jefferies	Hold
Sep-06-24	Initiated	Craig Hallum	Buy
Jan-05-22	Initiated	William Blair	Outperform
Dec-08-21	Initiated	Robert W. Baird	Outperform
Aug-09-21	Resumed	Maxim Group	Buy
Oct-22-20	Initiated	H.C. Wainwright	Buy
Oct-08-20	Initiated	Piper Sandler	Overweight

View All

Cardiff Oncology Inc Stock (CRDF) Latest News

Aug 14, 2026

Cardiff Oncology (CRDF) asks investors to double authorized common shares - Stock Titan

Aug 14, 2026

Aug 12, 2026

CARDIFF ONCOLOGY, INC. : WILLIAM BLAIR CUTS TO MARKET PERFORM RATING - webull.com

Aug 12, 2026

Analysts Offer Insights on Healthcare Companies: Neurogene (NGNE) and Cardiff Oncology (CRDF) - The Globe and Mail

Aug 12, 2026

CRDF Downgraded by William Blair -- Rating Changed to Market Per - GuruFocus

Aug 12, 2026

William Blair Downgrades Cardiff Oncology to Market Perform From Outperform - marketscreener.com

Aug 12, 2026

Piper Sandler Maintains Cardiff Oncology(CRDF.US) With Buy Rating, Maintains Target Price $6 - Moomoo

Aug 12, 2026

William Blair downgrades Cardiff Oncology stock rating on rights uncertainty - Investing.com

Aug 12, 2026

William Blair downgrades Cardiff Oncology stock rating on rights uncertainty By Investing.com - Investing.com Canada

Aug 12, 2026

Cardiff Oncology earnings missed by $0.02, revenue topped estimates - Investing.com Canada

Aug 12, 2026

Aug 11, 2026

Cardiff Oncology (NASDAQ:CRDF) Releases Earnings Results, Misses Expectations By $0.02 EPS - MarketBeat

Aug 11, 2026

Cardiff Oncology Reports Second Quarter 2026 Results and Provides Business Update - The Manila Times

Aug 11, 2026

Cardiff Oncology (NASDAQ: CRDF) cuts R&D spend but flags going concern risk - Stock Titan

Aug 11, 2026

Cardiff Oncology, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com

Aug 11, 2026

Aug 07, 2026